{
    "id": 2553,
    "fullName": "RET V804M",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RET V804M lies within the protein kinase domain of the Ret protein (UniProt.org). V804M confers a gain of function on the Ret protein, resulting in increased kinase activity, cell transformation (PMID: 16469774), and is considered a gatekeeper due to lack of response to some inhibitors, including cabozantinib and vandetanib (PMID: 23811235, PMID: 27712045).",
            "references": [
                {
                    "id": 1053,
                    "pubMedId": 16469774,
                    "title": "A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16469774"
                },
                {
                    "id": 602,
                    "pubMedId": 23811235,
                    "title": "Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23811235"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 8444,
                    "pubMedId": 27712045,
                    "title": "Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27712045"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "V804M",
    "createDate": "11/11/2014",
    "updateDate": "10/17/2018",
    "referenceTranscriptCoordinates": {
        "id": 125426,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43119548G>A",
        "cDna": "c.2410G>A",
        "protein": "p.V804M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET V804M in culture (PMID: 16507829).",
            "molecularProfile": {
                "id": 2412,
                "profileName": "RET V804M"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2736,
                    "pubMedId": 16507829,
                    "title": "BAY 43-9006 inhibition of oncogenic RET mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16507829"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804M (PMID: 26126987).",
            "molecularProfile": {
                "id": 2412,
                "profileName": "RET V804M"
            },
            "therapy": {
                "id": 4089,
                "therapyName": "Pz-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5385,
                    "pubMedId": 26126987,
                    "title": "Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26126987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14147,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selpercatinib (LOXO-292) treatment resulted in partial response in a thyroid medullary cancer patientharboring RET V804M (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).",
            "molecularProfile": {
                "id": 2412,
                "profileName": "RET V804M"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11479,
                    "pubMedId": null,
                    "title": "A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.",
                    "url": "https://meetinglibrary.asco.org/record/161573/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1852,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines expressing RET V804M demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",
            "molecularProfile": {
                "id": 2412,
                "profileName": "RET V804M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 602,
                    "pubMedId": 23811235,
                    "title": "Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23811235"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3422,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RET V804M demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).",
            "molecularProfile": {
                "id": 2412,
                "profileName": "RET V804M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3687,
                    "pubMedId": 15184865,
                    "title": "Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15184865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11247,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AD80 inhibited RET phosphorylation and growth of transformed cells expressing KIF5B-RET with RET V804M in culture (PMID: 28615362).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14415,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing KIF5B-RET and RET V804M were sensitive to treatment with Selpercatinib (LOXO-292) in culture, demonstrating decreased cell proliferation (PMID: 29912274).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3185,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) resulted in decreased autophosphorylation of Ret and reduced phosphorylation of Akt and Erk in transformed cells expressing both KIF5B-RET and RET V804M in culture (PMID: 25349307).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3119,
                    "pubMedId": 25349307,
                    "title": "Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25349307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14416,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14419,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET V804M in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited proliferation of cells expressing KIF5B-RET with RET V804M in culture (PMID: 29657135).",
            "molecularProfile": {
                "id": 12735,
                "profileName": "KIF5B - RET RET V804M"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10660,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224).",
            "molecularProfile": {
                "id": 27716,
                "profileName": "RET C634R RET V804M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8446,
                    "pubMedId": 19029224,
                    "title": "Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19029224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11248,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AD80 inhibited RET phosphorylation and growth of transformed cells expressing CCDC6-RET with RET V804M in culture (PMID: 28615362).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20218,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in initial tumor regression in colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET, however, tumors reemerged in 4 of 5 models, and 1 of 4 was found to have acquired RET V804M alone and 1 had both RET V804M and G810S in trans (PMID: 31988000).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14461,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer patient-derived xenograft (PDX) model harboring both CCDC6-RET and RET V804M was sensitive to treatment with Selpercatinib (LOXO-292), demonstrating tumor growth inhibition (PMID: 29912274).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21320,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-5010 (BOS172738) treatment resulted in durable tumor regression in a patient-derived xenograft (PDX) model of colorectal cancer harboring RET V804M in the context of CCDC6-RET fusion (Cancer Res 2019;79(13 Suppl):Abstract nr 2199).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 9591,
                "therapyName": "DS-5010",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18455,
                    "pubMedId": null,
                    "title": "BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11254,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AD80 resulted in decreased tumor cell proliferation and tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring CCDC6-RET with RET V804M (PMID: 28615362).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5915,
                "therapyName": "AD80",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9186,
                    "pubMedId": 28615362,
                    "title": "Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13497,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited tumor growth in a patient-derived xenograft (PDX) model of colorectal cancer harboring RET V804M in the context of CCDC6-RET (PMID: 29657135).",
            "molecularProfile": {
                "id": 27932,
                "profileName": "CCDC6 - RET RET V804M"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13698,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Compound germline RET V840M and S904C mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 29378,
                "profileName": "RET V804M RET S904C"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13695,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Compound germline RET V840M and Y806C mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 29379,
                "profileName": "RET V804M RET Y806C"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13694,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Compound germline RET V840M and E805K mutations result in multiple endocrine neoplasia, type 2B (MEN 2B), which is associated with high risk of developing thyroid medullary carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 29380,
                "profileName": "RET V804M RET E805K"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14404,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Ofev (nintedanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 831,
                "therapyName": "Nintedanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14402,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Lenvima (lenvatinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14403,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Caprelsa (vandetanib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14401,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell expressing RET L730V and V804M in the context of KIF5B-RET were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 29908090).",
            "molecularProfile": {
                "id": 30006,
                "profileName": "KIF5B - RET RET L730V RET V804M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11579,
                    "pubMedId": 29908090,
                    "title": "Drug resistance profiles of mutations in the RET kinase domain.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29908090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14464,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with thyroid medullary cancer harboring RET M918T and RET V804M demonstrated an initial response to Selpercatinib (LOXO-292), which included a decrease in allelic fraction of RET M918T and RET V804M over 8 weeks and a radiographic response of nearly 54% post 6.9 months of treatment (PMID: 29912274; NCT03157128).",
            "molecularProfile": {
                "id": 30021,
                "profileName": "RET V804M RET M918T"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14462,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with thyroid medullary carcinoma harboring RET M918T progressed on multiple therapies, including Nexavar (sorafenib), Caprelsa (vandetanib), Cometriq (cabozantinib), MGCD-516 (sitravatinib), and RXDX-105 (CEP-32496), and upon progression with the combination therapy, Caprelsa (vandetanib) and Afinitor (everolimus), cell-free DNA testing revealed RET M918T and acquisition of a secondary drug resistant mutation, RET V804M (PMID: 29912274; NCT03157128).",
            "molecularProfile": {
                "id": 30021,
                "profileName": "RET V804M RET M918T"
            },
            "therapy": {
                "id": 1163,
                "therapyName": "Everolimus + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14465,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma initially treated with chemotherapy and immunotherapy was found to harbor KIF5B-RET, and was then treated with Alecensa (alectinib), which resulted in an intracranial response, but eventually led to further progression (PMID: 29912274; NCT03157128).",
            "molecularProfile": {
                "id": 30021,
                "profileName": "RET V804M RET M918T"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20214,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selpercatinib (LOXO-292) treatment resulted in initial tumor regression in colorectal cancer patient-derived xenograft (PDX) models harboring CCDC6-RET, however, tumors reemerged in 4 of 5 models, and 3 of 4 were found to have acquired RET G810S, one with a co-incident RET V804M mutation in trans (PMID: 31988000).",
            "molecularProfile": {
                "id": 34941,
                "profileName": "CCDC6 - RET RET V804M RET G810S"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17728,
                    "pubMedId": 31988000,
                    "title": "RET Solvent Front Mutations Mediate Acquired\u00a0Resistance to Selective RET Inhibition in\u00a0RET-Driven Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31988000"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2412,
            "profileName": "RET V804M",
            "profileTreatmentApproaches": [
                {
                    "id": 382,
                    "name": "RET Inhibitor",
                    "profileName": "RET V804M"
                }
            ]
        },
        {
            "id": 12735,
            "profileName": "KIF5B - RET RET V804M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27716,
            "profileName": "RET C634R RET V804M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27932,
            "profileName": "CCDC6 - RET RET V804M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29378,
            "profileName": "RET V804M RET S904C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29379,
            "profileName": "RET V804M RET Y806C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29380,
            "profileName": "RET V804M RET E805K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30006,
            "profileName": "KIF5B - RET RET L730V RET V804M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30021,
            "profileName": "RET V804M RET M918T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34941,
            "profileName": "CCDC6 - RET RET V804M RET G810S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 125426,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43119548G>A",
            "cDna": "c.2410G>A",
            "protein": "p.V804M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 125427,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43119548G>A",
            "cDna": "c.2410G>A",
            "protein": "p.V804M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}